Stocks · News reference
AbbVie shares gained 1.4% to close at $256.92 on Thursday while Transocean shares rose 0.4% to settle at $5.32 during the session.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Submission supported by data from Phase 3 pivotal AFFIRM studyIf approved, adult Crohn's disease patients will have an additional option for induction of risankizumab which is already approved for intravenous (IV)
Read original at benzingaBillionaire hedge fund manager Ken Griffin's Citadel increased its stake in AbbVie by 547% in Q2, adding 2.7 million shares worth approximately $798 million. The move reflects a defensive investment strategy into a stable dividend stock. AbbVie, a Dividend King with 54 consecutive years of dividend increases, currently yields 2.6% and has 75% of Wall Street analysts rating it as a buy with a median price target of $282.50.
Read original at the-motley-foolBillionaire hedge fund manager Ken Griffin recently increased his stakes in AbbVie and Abbott Laboratories through his fund Citadel. The article analyzes whether retail investors should follow his lead, highlighting AbbVie's transition from Humira to new immunology drugs like Skyrizi and Rinvoq with expansion into oncology, and Abbott's strong positions in diabetes care, diagnostics, and medical devices. The author suggests both stocks merit consideration as part of a long-term healthcare allocation based on their business fundamentals rather than simply following Griffin's moves.
Read original at the-motley-foolCerebras Systems and Advanced Micro Devices are both benefiting from AI infrastructure growth. While AMD offers greater scale, profitability and diversification with Data Center revenues more than doubling, Cerebras appears to have an edge with faster growth expectations, $25.4B in remaining performance obligations, and strong partnerships with OpenAI and AWS. Cerebras expects core revenues to more than triple in 2027, though it remains unprofitable with customer concentration risks.
Read original at zacks-investment-researchCathie Wood's Ark Invest added to positions in Broadcom, Cerebras Systems, and Cloudflare on Wednesday, taking advantage of market pullbacks. All three stocks have declined 14-53% from recent all-time highs but show strong revenue growth and business fundamentals, with Broadcom expected to report 85% revenue growth and Cerebras showing 74% growth despite customer concentration concerns.
Read original at the-motley-foolOn Wednesday, Aug. 26, 2026, Ark Invest sold CrowdStrike and AMD shares after CrowdStrike's record quarter.
Read original at benzinga